Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jun;115(3):534–538. doi: 10.1111/j.1476-5381.1995.tb16367.x

Effect of platelet-derived growth factor on voltage-operated calcium channels in rabbit isolated ear artery cells.

S Wijetunge 1, A D Hughes 1
PMCID: PMC1908398  PMID: 7582469

Abstract

1. Platelet derived growth factor (PDGF), AB and BB isoforms (100 pM) increased calcium channel currents measured by whole cell voltage clamp technique in single vascular smooth muscle cells isolated from rabbit ear arteries. 2. Tyrphostin-23 (100 microM) a selective inhibitor of protein tyrosine kinases, reduced calcium channel currents. Pre-incubation with tyrphostin-23 prevented PDGF-AB induced increase in calcium channel currents. However, in these same cells 10 nM (+)-202791, a dihydropyridine calcium channel agonist, did increase calcium channel currents. 3. Bistyrphostin (10 microM), a selective inhibitor of epidermal growth factor (EGF)-kinase also reduced calcium channel currents and inhibited PDGF-AB-induced increases in calcium channel currents. 4. Genistein (100 microM) a selective inhibitor of tyrosine kinases, structurally unrelated to the tryphostins, also inhibited calcium channel currents and pre-incubation with genistein prevented the PDGF-AB-induced rise in calcium channel currents. 5. These results indicate that PDGF increases calcium channel currents in vascular smooth muscle. This action of PDGF probably involves a tyrosine kinase.

Full text

PDF
534

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaronson P. I., Bolton T. B., Lang R. J., MacKenzie I. Calcium currents in single isolated smooth muscle cells from the rabbit ear artery in normal-calcium and high-barium solutions. J Physiol. 1988 Nov;405:57–75. doi: 10.1113/jphysiol.1988.sp017321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987 Apr 25;262(12):5592–5595. [PubMed] [Google Scholar]
  3. Benham C. D., Bolton T. B. Spontaneous transient outward currents in single visceral and vascular smooth muscle cells of the rabbit. J Physiol. 1986 Dec;381:385–406. doi: 10.1113/jphysiol.1986.sp016333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berk B. C., Alexander R. W., Brock T. A., Gimbrone M. A., Jr, Webb R. C. Vasoconstriction: a new activity for platelet-derived growth factor. Science. 1986 Apr 4;232(4746):87–90. doi: 10.1126/science.3485309. [DOI] [PubMed] [Google Scholar]
  5. Berk B. C., Alexander R. W. Vasoactive effects of growth factors. Biochem Pharmacol. 1989 Jan 15;38(2):219–225. doi: 10.1016/0006-2952(89)90030-0. [DOI] [PubMed] [Google Scholar]
  6. Bilder G. E., Krawiec J. A., McVety K., Gazit A., Gilon C., Lyall R., Zilberstein A., Levitzki A., Perrone M. H., Schreiber A. B. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol. 1991 Apr;260(4 Pt 1):C721–C730. doi: 10.1152/ajpcell.1991.260.4.C721. [DOI] [PubMed] [Google Scholar]
  7. Bobik A., Campbell J. H. Vascular derived growth factors: cell biology, pathophysiology, and pharmacology. Pharmacol Rev. 1993 Mar;45(1):1–42. [PubMed] [Google Scholar]
  8. Bolton T. B. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev. 1979 Jul;59(3):606–718. doi: 10.1152/physrev.1979.59.3.606. [DOI] [PubMed] [Google Scholar]
  9. Cadena D. L., Gill G. N. Receptor tyrosine kinases. FASEB J. 1992 Mar;6(6):2332–2337. doi: 10.1096/fasebj.6.6.1312047. [DOI] [PubMed] [Google Scholar]
  10. Gazit A., Yaish P., Gilon C., Levitzki A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344–2352. doi: 10.1021/jm00130a020. [DOI] [PubMed] [Google Scholar]
  11. Hamill O. P., Marty A., Neher E., Sakmann B., Sigworth F. J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981 Aug;391(2):85–100. doi: 10.1007/BF00656997. [DOI] [PubMed] [Google Scholar]
  12. Hart C. E., Forstrom J. W., Kelly J. D., Seifert R. A., Smith R. A., Ross R., Murray M. J., Bowen-Pope D. F. Two classes of PDGF receptor recognize different isoforms of PDGF. Science. 1988 Jun 10;240(4858):1529–1531. doi: 10.1126/science.2836952. [DOI] [PubMed] [Google Scholar]
  13. Heldin C. H., Ernlund A., Rorsman C., Rönnstrand L. Dimerization of B-type platelet-derived growth factor receptors occurs after ligand binding and is closely associated with receptor kinase activation. J Biol Chem. 1989 May 25;264(15):8905–8912. [PubMed] [Google Scholar]
  14. Heldin C. H., Johnsson A., Wennergren S., Wernstedt C., Betsholtz C., Westermark B. A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Nature. 1986 Feb 6;319(6053):511–514. doi: 10.1038/319511a0. [DOI] [PubMed] [Google Scholar]
  15. Hollenberg M. D. The acute actions of growth factors in smooth muscle systems. Life Sci. 1994;54(4):223–235. doi: 10.1016/0024-3205(94)00811-6. [DOI] [PubMed] [Google Scholar]
  16. Hollenberg M. D. Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends Pharmacol Sci. 1994 Apr;15(4):108–114. doi: 10.1016/0165-6147(94)90046-9. [DOI] [PubMed] [Google Scholar]
  17. Hughes A. D., Hering S., Bolton T. B. Evidence that agonist and antagonist enantiomers of the dihydropyridine PN 202-791 act at different sites on the voltage-dependent calcium channel of vascular muscle. Br J Pharmacol. 1990 Sep;101(1):3–5. doi: 10.1111/j.1476-5381.1990.tb12076.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hughes A. D. Increase in tone and intracellular Ca2+ in rabbit isolated ear artery by platelet-derived growth factor. Br J Pharmacol. 1995 Jan;114(1):138–142. doi: 10.1111/j.1476-5381.1995.tb14917.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Johnsson A., Heldin C. H., Westermark B., Wasteson A. Platelet-derived growth factor: identification of constituent polypeptide chains. Biochem Biophys Res Commun. 1982 Jan 15;104(1):66–74. doi: 10.1016/0006-291x(82)91941-6. [DOI] [PubMed] [Google Scholar]
  20. Kobayashi S., Nishimura J., Kanaide H. Cytosolic Ca2+ transients are not required for platelet-derived growth factor to induce cell cycle progression of vascular smooth muscle cells in primary culture. Actions of tyrosine kinase. J Biol Chem. 1994 Mar 25;269(12):9011–9018. [PubMed] [Google Scholar]
  21. Levitzki A., Gilon C. Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol Sci. 1991 May;12(5):171–174. doi: 10.1016/0165-6147(91)90538-4. [DOI] [PubMed] [Google Scholar]
  22. Magni M., Meldolesi J., Pandiella A. Ionic events induced by epidermal growth factor. Evidence that hyperpolarization and stimulated cation influx play a role in the stimulation of cell growth. J Biol Chem. 1991 Apr 5;266(10):6329–6335. [PubMed] [Google Scholar]
  23. Nilsson J., Sjölund M., Palmberg L., Von Euler A. M., Jonzon B., Thyberg J. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis. 1985 Dec;58(1-3):109–122. doi: 10.1016/0021-9150(85)90059-0. [DOI] [PubMed] [Google Scholar]
  24. Pazin M. J., Williams L. T. Triggering signaling cascades by receptor tyrosine kinases. Trends Biochem Sci. 1992 Oct;17(10):374–378. doi: 10.1016/0968-0004(92)90003-r. [DOI] [PubMed] [Google Scholar]
  25. Rhee S. G. Inositol phospholipids-specific phospholipase C: interaction of the gamma 1 isoform with tyrosine kinase. Trends Biochem Sci. 1991 Aug;16(8):297–301. doi: 10.1016/0968-0004(91)90122-c. [DOI] [PubMed] [Google Scholar]
  26. Ross R. Platelet-derived growth factor. Lancet. 1989 May 27;1(8648):1179–1182. doi: 10.1016/s0140-6736(89)92760-8. [DOI] [PubMed] [Google Scholar]
  27. Sauro M. D., Thomas B. Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s). J Pharmacol Exp Ther. 1993 Dec;267(3):1119–1125. [PubMed] [Google Scholar]
  28. Schlessinger J. How receptor tyrosine kinases activate Ras. Trends Biochem Sci. 1993 Aug;18(8):273–275. doi: 10.1016/0968-0004(93)90031-h. [DOI] [PubMed] [Google Scholar]
  29. Schlessinger J., Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron. 1992 Sep;9(3):383–391. doi: 10.1016/0896-6273(92)90177-f. [DOI] [PubMed] [Google Scholar]
  30. Seifert R. A., Hart C. E., Phillips P. E., Forstrom J. W., Ross R., Murray M. J., Bowen-Pope D. F. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem. 1989 May 25;264(15):8771–8778. [PubMed] [Google Scholar]
  31. Selinfreund R. H., Blair L. A. Insulin-like growth factor-I induces a rapid increase in calcium currents and spontaneous membrane activity in clonal pituitary cells. Mol Pharmacol. 1994 Jun;45(6):1215–1220. [PubMed] [Google Scholar]
  32. Siegelbaum S. A. Channel regulation. Ion channel control by tyrosine phosphorylation. Curr Biol. 1994 Mar 1;4(3):242–245. doi: 10.1016/s0960-9822(00)00054-3. [DOI] [PubMed] [Google Scholar]
  33. Stein O., Halperin G., Stein Y. Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum. Arteriosclerosis. 1987 Nov-Dec;7(6):585–592. doi: 10.1161/01.atv.7.6.585. [DOI] [PubMed] [Google Scholar]
  34. Stroobant P., Waterfield M. D. Purification and properties of porcine platelet-derived growth factor. EMBO J. 1984 Dec 1;3(12):2963–2967. doi: 10.1002/j.1460-2075.1984.tb02241.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tsuda T., Kawahara Y., Shii K., Koide M., Ishida Y., Yokoyama M. Vasoconstrictor-induced protein-tyrosine phosphorylation in cultured vascular smooth muscle cells. FEBS Lett. 1991 Jul 8;285(1):44–48. doi: 10.1016/0014-5793(91)80721-e. [DOI] [PubMed] [Google Scholar]
  36. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990 Apr 20;61(2):203–212. doi: 10.1016/0092-8674(90)90801-k. [DOI] [PubMed] [Google Scholar]
  37. Wijetunge S., Aalkjaer C., Schachter M., Hughes A. D. Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun. 1992 Dec 30;189(3):1620–1623. doi: 10.1016/0006-291x(92)90262-j. [DOI] [PubMed] [Google Scholar]
  38. Williams J. S., Grupp I. L., Grupp G., Vaghy P. L., Dumont L., Schwartz A., Yatani A., Hamilton S., Brown A. M. Profile of the oppositely acting enantiomers of the dihydropyridine 202-791 in cardiac preparations: receptor binding, electrophysiological, and pharmacological studies. Biochem Biophys Res Commun. 1985 Aug 30;131(1):13–21. doi: 10.1016/0006-291x(85)91763-2. [DOI] [PubMed] [Google Scholar]
  39. Young S. W., Poole R. C., Hudson A. T., Halestrap A. P., Denton R. M., Tavaré J. M. Effects of tyrosine kinase inhibitors on protein kinase-independent systems. FEBS Lett. 1993 Feb 1;316(3):278–282. doi: 10.1016/0014-5793(93)81308-m. [DOI] [PubMed] [Google Scholar]
  40. van Breemen C., Saida K. Cellular mechanisms regulating [Ca2+]i smooth muscle. Annu Rev Physiol. 1989;51:315–329. doi: 10.1146/annurev.ph.51.030189.001531. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES